March 2, 2018 / 10:38 AM / 6 months ago

BRIEF-FDA To Review Dupixent® (Dupilumab) As Potential Treatment For Moderate-To-Severe Asthma

March 2 (Reuters) - Regeneron Pharmaceuticals Inc:

* FDA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR MODERATE-TO-SEVERE ASTHMA

* ‍PER PRESCRIPTION DRUG USER FEE ACT, TARGET ACTION DATE IS OCTOBER 20, 2018​

* ‍POTENTIAL USE OF DUPIXENT IN ASTHMA IS CURRENTLY UNDER CLINICAL DEVELOPMENT​

* SAFETY AND EFFICACY FOR ‍DUPIXENT IN ASTHMA HAVE NOT BEEN FULLY EVALUATED BY ANY REGULATORY AUTHORITY​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below